Insight

Sep 11, 2024, 07:24

A roadmap for designing better immunotherapies – Cancer Research Institute

Cancer Research Institute (CRI) made the following post on LinkedIn:

“New findings from researchers, including 2022 William B. Coley Award recipient Dr. Judy Lieberman of Boston Children’s Hospital, indicate that tumors edit multiple genes to avoid recognition by the immune system. Published in Springer Nature Group’s Nature Immunology, the study additionally demonstrates a way to override these edits, by curbing tumor growth in a human-like mouse model of breast cancer, ‘which is notoriously resistant to immunotherapy.’ Discover how this study could provide a roadmap for designing better immunotherapies.”

Read further.
Source: Cancer Research Institute (CRI)/LinkedIn

Boston Children’s Hospital Breast Cancer cancer Cancer research Cancer Research Institute CRI Gene Editing immune system immunotherapy Judy Lieberman Nature Immunology OncoDaily Oncology Springer Nature Group

Does Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Miranda McKeon: Battling Breast Cancer at 19, Inspiring Millions on Instagram